How door-to-door canvassing slowed an epidemicMassachusetts Institute of Technology (MIT)
Liberia was the epicenter of a high-profile Ebola outbreak in 2014-15, which led to more than 10,000 deaths in West Africa.
Interacting contagious diseases like influenza and pneumonia—and perhaps coronavirus too—follow the same complex spreading patterns as social trends, like the adoption of new slang or technologies. This new finding, published in Nature Physics, could lead to better tracking and intervention when multiple diseases spread through a population at the same time.
Robert Stahelin studies some of the world’s deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates. Stahelin, professor at Purdue University, examines how these viruses take advantage of human host cells.
It's no coincidence that some of the worst viral disease outbreaks in recent years -- SARS, MERS, Ebola, Marburg and likely the newly arrived 2019-nCoV virus -- originated in bats.
A device to quickly capture and identify various strains of virus has been developed, according to researchers at Penn State and New York University.
Scientists using specialized beamlines at Argonne's Structural Biology Center (SBC), a facility for macromolecular crystallography at the Advanced Photon Source, derived insights that led to the discovery of a promising new drug for Ebola.
La Jolla Institute for Immunology (LJI) is placing their confidence in Berkeley Lights’ Beacon® Optofluidic Platform and B cell antibody discovery workflow to accelerate the discovery of rare and lifesaving antibodies for the treatment of re-emerging and emerging diseases.
In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).
WCS (Wildlife Conservation Society) and NIH (National Institutes of Health) scientists partnered with the Republic of Congo Ministry of Health to develop a low-cost educational outreach program and surveillance system for wildlife mortality that has continued now for over a decade.